Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines Insights: Merkel Cell Carcinoma, Version 1.2024. Journal of the National Comprehensive Cancer Network : JNCCN Schmults, C. D., Blitzblau, R., Aasi, S. Z., Alam, M., Amini, A., Bibee, K., Bolotin, D., Bordeaux, J., Chen, P., Contreras, C. M., DiMaio, D., Donigan, J. M., Farma, J. M., Ghosh, K., Harms, K., Ho, A. L., Lukens, J. N., Manber, S., Mark, L., Medina, T., Nehal, K. S., Nghiem, P., Olino, K., Park, S., Patel, T., Puzanov, I., Rich, J., Sekulic, A., Shaha, A. R., Srivastava, D., Thomas, V., Tomblinson, C., Venkat, P., Xu, Y. G., Yu, S., Yusuf, M., McCullough, B., Espinosa, S. 2024; 22 (1D): e240002

Abstract

The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments from expert review from panel members, institutional review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled "Clinical N0 Disease, Locally Advanced MCC." This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term "nonsurgical" by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.

View details for DOI 10.6004/jnccn.2024.0002

View details for PubMedID 38244274